A Grade 3 Vaccine-Related Adverse Event is Serious
When Moderna, Inc. announced on May 18, 2020 the results of a Phase 1 human clinical trial for its experimental mRNA-1273 vaccine for COVID-19, the biotechnology company said the vaccine had produced no “serious adverse events” (SAEs) among the 45 people who participated in the trial and that it considered the vaccine to be “generally […]
Children Recruited in U.K. for COVID-19 Vaccine Trial
The University of Oxford’s Jenner Institute and Oxford Vaccine Group in the United Kingdom has announced that its researchers have begun recruiting children aged five to 12 years for phase II and phase III clinical trials testing an experimental COVID-19 vaccine the university is developing in partnership with AstraZeneca plc.1 Oxford’s ChAdOx1 nCov-19 (“chimpanzee adenovirus […]
COVID-19 Vaccine Will Likely Be Given Multiple Times, Perhaps Annually
In an interview with the JAMA on June 2, 2020, Anthony Fauci, MD, director of the U.S. National Institute of Allergy and Infectious Diseases (NIAID) said that while he was “cautiously optimistic” about the effectiveness of the vaccines being developed for COVID-19, he was concerned that any protection the vaccines may provide might only be temporary. […]
Pfizer/BioNTech Target Fall 2020 for COVID-19 Vaccine Availability
In recent weeks Inovio Pharmaceuticals of Pennsylvania and representatives of the German biotechnology firm CureVac AG and the University of Oxford in the United Kingdom have announced that their experimental COVID-19 vaccines will be ready for use by September 2020. On Apr. 29, 2020, Pfizer, Inc. of New York stated in a news release that […]
